Ontology highlight
ABSTRACT:
SUBMITTER: Gold KA
PROVIDER: S-EPMC4201000 | biostudies-literature | 2014 Oct
REPOSITORIES: biostudies-literature
Gold Kathryn A KA Lee J Jack JJ Harun Nusrat N Tang Ximing X Price Justina J Kawedia Jitesh D JD Tran Hai T HT Erasmus Jeremy J JJ Blumenschein George R GR William William N WN Wistuba Ignacio I II Johnson Faye M FM
The oncologist 20140828 10
<h4>Background</h4>EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine the maximum tolerated dose (MTD), pharmacokinetic drug interactions, biomarkers, and efficacy in NSCLC.<h4>Methods</h4>The phase I 3+3 dose-escalation study enrolled patients with solid tumors ...[more]